Chronic Lymphocytic Leukemia Clinical Trials in Cincinnati, Ohio

9 studies are recruiting for chronic lymphocytic leukemia in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

   This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymph…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

   Locations

   632 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04269902 on ClinicalTrials.gov

2. A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

   This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study interve…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Oncology Hematology Care Inc, Cincinnati, Ohio

   Locations

   50 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07218341 on ClinicalTrials.gov

3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

   This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the earl…

   Stage

   Not phased

   Ages

   40 to 75

   Site

   Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

   Locations

   745 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT05334069 on ClinicalTrials.gov

4. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

   The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituxi…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Hematology Care Clinical Trials, Llc, Cincinnati, Ohio

   Locations

   195 in total

   Run by

   BeOne Medicines

   See if you can join NCT06943872 on ClinicalTrials.gov

5. Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

   This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

   Stage

   Phase 1

   Ages

   13 and older

   Site

   Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

   Locations

   8 in total

   Run by

   Newave Pharmaceutical Inc

   See if you can join NCT04771572 on ClinicalTrials.gov

6. Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

   This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Run by

   Zulfa Omer

   See if you can join NCT07014917 on ClinicalTrials.gov

7. Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

   This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Run by

   Zulfa Omer

   See if you can join NCT07108998 on ClinicalTrials.gov

8. LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

   Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Cincinnati Medical Center, Cincinnati, Ohio

   Run by

   Zulfa Omer

   See if you can join NCT06978088 on ClinicalTrials.gov

9. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

   This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Locations

   45 in total

   Run by

   Kartos Therapeutics, Inc.

   See if you can join NCT04502394 on ClinicalTrials.gov